Ironwood Pharmaceuticals (IRWD) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 115.8% versus a gain of 5.3%. Over five years, ZVRA leads with a +16.6% price change compared with -72.0% for IRWD. Zevra Therapeutics is the larger company by market cap ($676.4 million vs $631.2 million), about 1.1 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (2.5x vs 10.6x for Zevra Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | ZVRA |
|---|---|---|
| Share price | $3.82 | $11.39 |
| Market cap | $631.22M | $676.38M |
| 1-day change | -1.29% | +3.55% |
| YTD return | +13.35% | +27.12% |
| 1-year return | +115.82% | +5.27% |
| 5-year return | -72.04% | +16.58% |
| P/E ratio (TTM) | 5.03 | 11.99 |
| Forward P/E | 2.55 | 10.58 |
| EPS (TTM) | $0.76 | $0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $15.04 |
| 52-week low | $1.41 | $8.01 |
| Distance from 52-week high | -33.91% | -24.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +59.69% | +119.49% |
| Average volume | 2.01M | 1.09M |
| Shares outstanding | 165.24M | 59.38M |
| Employees | 100 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed ZVRA by 110.6 percentage points over the past year.
- Zevra Therapeutics trades at a higher earnings multiple (12.0x vs 5.0x trailing P/E).
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
IRWD vs ZVRA FAQ
Which is bigger, Ironwood Pharmaceuticals or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $676.38M compared with $631.22M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, IRWD or ZVRA?
IRWD returned +115.82% over the past 12 months, compared with +5.27% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IRWD or ZVRA?
IRWD has the lower trailing P/E at 5.0, versus 12.0 for ZVRA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ironwood Pharmaceuticals and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.